Stepping up flu vaccine supply – Seqirus to supply additional two million flu vaccines to Australia
Local flu vaccine manufacturer Seqirus will go back into production to supply Australians approximately two million additional flu vaccines for the 2020 flu season.
The decision to make the extra doses comes on the back of strong early demand for influenza vaccinations, and after discussions with the Australian Government about the need to ensure as many Australians as possible can access flu vaccines.
“We’ve seen strong demand for flu vaccines earlier than usual – and this is a positive trend, because we know that flu vaccination programs will be more important than ever due to the COVID-19 pandemic,” said Seqirus Executive Director Commercial Operations, Danielle Dowell.
“As an Australian-owned company, Seqirus is incredibly proud to be able to partner with the Australian Government to supply these additional doses.
“It’s important to note that the supply of these additional doses won’t be instantaneous – our team will be working hard to manufacture doses, but patients should phone their clinic or pharmacy ahead of time to ensure the vaccines have arrived and are available.
“We will be working closely with distributors across the country to make sure the vaccines are available as soon as possible, in areas of high demand.”
Seqirus was already on track to supply Australians a record number of influenza vaccines this season, and this additional stock will take our total supply to around nine million influenza vaccines.
Additional doses will be produced in Parkville, Victoria, and will be released into the private market – available at GPs, pharmacies and immunisation providers across the country.
For 100 years Seqirus – a CSL company – has been on the front line in the fight against influenza in Australia, and is proud to operate Australia’s only local manufacturing facility for seasonal and pandemic influenza vaccines.